Therefore, the aim of this study was to assess whether EZH2 played a role in myeloid differentiation of human non-APL AML, which had not been previously evaluated, and, if so, whether small molecule inhibitors of EZH2 could be effective in combination with ATRA. This evidence concerns the gene EZH2 and acute myeloid leukemia.